We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical (ISRG) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Intuitive Surgical (ISRG - Free Report) closed at $558.29, marking a -0.08% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. Elsewhere, the Dow gained 0.54%, while the tech-heavy Nasdaq added 0.76%.
Heading into today, shares of the robotic surgery system company had gained 4.23% over the past month, outpacing the Medical sector's gain of 2.18% and the S&P 500's gain of 2.53% in that time.
ISRG will be looking to display strength as it nears its next earnings release. In that report, analysts expect ISRG to post earnings of $2.67 per share. This would mark year-over-year growth of 9.43%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $971.94 million, up 14.68% from the year-ago period.
ISRG's full-year Zacks Consensus Estimates are calling for earnings of $12.01 per share and revenue of $4.30 billion. These results would represent year-over-year changes of +9.28% and +15.42%, respectively.
It is also important to note the recent changes to analyst estimates for ISRG. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ISRG is holding a Zacks Rank of #4 (Sell) right now.
Investors should also note ISRG's current valuation metrics, including its Forward P/E ratio of 46.53. This valuation marks a premium compared to its industry's average Forward P/E of 35.07.
Investors should also note that ISRG has a PEG ratio of 3.62 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 2.65 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Intuitive Surgical (ISRG) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Intuitive Surgical (ISRG - Free Report) closed at $558.29, marking a -0.08% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. Elsewhere, the Dow gained 0.54%, while the tech-heavy Nasdaq added 0.76%.
Heading into today, shares of the robotic surgery system company had gained 4.23% over the past month, outpacing the Medical sector's gain of 2.18% and the S&P 500's gain of 2.53% in that time.
ISRG will be looking to display strength as it nears its next earnings release. In that report, analysts expect ISRG to post earnings of $2.67 per share. This would mark year-over-year growth of 9.43%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $971.94 million, up 14.68% from the year-ago period.
ISRG's full-year Zacks Consensus Estimates are calling for earnings of $12.01 per share and revenue of $4.30 billion. These results would represent year-over-year changes of +9.28% and +15.42%, respectively.
It is also important to note the recent changes to analyst estimates for ISRG. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ISRG is holding a Zacks Rank of #4 (Sell) right now.
Investors should also note ISRG's current valuation metrics, including its Forward P/E ratio of 46.53. This valuation marks a premium compared to its industry's average Forward P/E of 35.07.
Investors should also note that ISRG has a PEG ratio of 3.62 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 2.65 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.